Fenwick & West represented BioAge Labs, Inc. in the offering, and Cooley represented the underwriters. BioAge Labs, Inc. (Nasdaq: BIOA), a clinical-stage biopharmaceutical company developing therapeutic...
You must be a Standard 1 Year member to access this content.
Fenwick & West represented Belharra Therapeutics in the transaction. Belharra Therapeutics (Belharra) announced it has entered into a collaboration with Sanofi to advance the discovery of...
You must be a Standard 1 Year member to access this content.
Fenwick & West represented Hospital Billing & Collection Service, Ltd in the transaction. Hospital Billing & Collection Service, Ltd (“HBCS”), a tech-enabled RCM company that offers...
You must be a Standard 1 Year member to access this content.
Fenwick & West represented BioAge Labs in the transaction. BioAge Labs (BioAge) announced it completed the oversubscribed $170M Series D financing round led by Sofinnova Investments...
You must be a Standard 1 Year member to access this content.
Fenwick & West represented Eychonis, Inc. in the transaction. Eyconis, Inc. announced their formation and $150 million capital raise. Eyconis was formed and launched by Ascendis...
You must be a Standard 1 Year member to access this content.
Fenwick & West is representing Veracyte in the transaction, and Meitar is representing C2i Genomics. Veracyte, Inc. (Nasdaq: VCYT) announced it has entered into a definitive agreement...
You must be a Standard 1 Year member to access this content.
Fenwick & West represented Recludix Pharma in the deal. Recludix Pharma announced that it has entered into a strategic collaboration with Sanofi (NASDAQ: SNY) to develop and...
You must be a Standard 1 Year member to access this content.
Fenwick & West LLP represented DICE Therapeutics, Inc. in the transaction, while Kirkland & Ellis represented Eli Lilly and Company. Eli Lilly and Company (NYSE: LLY)...
You must be a Standard 1 Year member to access this content.
Fenwick & West LLP represented Chinook Therapeutics, Inc. on the transaction, while Hogan Lovells US LLP represented Novartis AG. Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company, announced...
You must be a Standard 1 Year member to access this content.
Fenwick represented Belharra Therapeutics on the deal. Belharra Therapeutics, a privately held drug discovery company with a novel photoaffinity-based, non-covalent chemoproteomics platform, announced its multi-year collaboration with...
You must be a Standard 1 Year member to access this content.
Fenwick represented Aceragen on the deal, Morgan Lewis advised Idera Pharmaceuticals. Aceragen, a privately-held biotechnology company addressing rare, orphan pulmonary and rheumatic diseases for which there...
You must be a Standard 1 Year member to access this content.
Fenwick represented Scribe Therapeutics on the deal. Scribe Therapeutics, a molecular engineering company pioneering a CRISPR by Design™ platform for genetic medicine, announced its strategic collaboration and...
You must be a Standard 1 Year member to access this content.
